-
-
-
-
-
-
-
AB Science reports its revenues for the year 2025 and provides an update on its activities
-
-
-
-
-
-
-
AB Science provides an update on its clinical development program.
-
-
-
-
-
-
-
AB Science receives US patent approval for masitinib cancer treatment
-
-
-
-
-
-
-
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share
-
-
-
-
-
-
-
AllianceBernstein (AB) Tops Q3 EPS by 1c
-
-
-
-
-
-
-
AB Announces September 30, 2025 Assets Under Management
-
-
-
-
-
-
-
AllianceBernstein (AB) Reports In-Line Q2 EPS, Misses on Revenue
-
1,199,633 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

